A novel Caenorhabditis elegans allele, smn-1(cb131), mimicking a mild form of spinal muscular atrophy, provides a convenient drug screening platform highlighting new and pre-approved compounds

Human Molecular Genetics

Volumn 20, Issue 2, 2011, Pages 245-260

  Sleigh, James N ^a   Buckingham, Steven D ^a   Esmaeili, Behrooz ^a   Viswanathan, Mohan ^b,c   Cuppen, Edwin ^d   Westlund, Bethany M ^b   Sattelle, David B ^a,e  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b Cambria Pharmaceuticals   (United States)

^c MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^d UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^e UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOPYRIDINE; AGENTS ACTING ON THE PERIPHERAL NERVOUS AND NEUROMUSCULAR SYSTEMS; AKLAVIN; GABOXADOL; METARAMINOL; N ACETYLNEURAMINIC ACID; SURVIVAL MOTOR NEURON PROTEIN 1; UNCLASSIFIED DRUG; ZIDOVUDINE;

ADULTHOOD; ALLELE; AMINO ACID SUBSTITUTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY HEIGHT; CAENORHABDITIS ELEGANS; CONTROLLED STUDY; DOSE RESPONSE; EGG LAYING; EXON; FEMALE; GENE ISOLATION; GENETIC ANALYSIS; GROWTH RETARDATION; HOMOZYGOSITY; LIFESPAN; NONHUMAN; PHENOTYPE; POINT MUTATION; PRIORITY JOURNAL; SPINAL MUSCULAR ATROPHY; SURVIVAL RATE; SYNAPTIC TRANSMISSION; WILD TYPE;

4-AMINOPYRIDINE; ALLELES; AMINO ACID SEQUENCE; ANIMALS; CAENORHABDITIS ELEGANS; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; HUMANS; MOLECULAR SEQUENCE DATA; MOTOR ACTIVITY; MUSCULAR ATROPHY, SPINAL; POINT MUTATION; SEQUENCE ALIGNMENT; SIALIC ACIDS; SMALL MOLECULE LIBRARIES; SURVIVAL OF MOTOR NEURON 1 PROTEIN;

ANIMALIA; CAENORHABDITIS ELEGANS;

EID: 78650557080     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/ddq459     Document Type: Article

References (105)

1. Pearn, J. (1978) Incidence, prevalence, and gene frequency studies of chronic childhood spinal muscular atrophy. J. Med. Genet., 15, 409-413.
2. Burghes, A.H. and Beattie, C.E. (2009) Spinal muscular atrophy: why do low levels of survival motor neuron protein make motor neurons sick? Nat. Rev. Neurosci., 10, 597-609.
3. Lefebvre, S., Burglen, L., Reboullet, S., Clermont,O., Burlet, P., Viollet, L., Benichou, B., Cruaud, C., Millasseau, P., Zeviani, M. et al. (1995) Identification and characterization of a spinal muscular atrophydetermining gene. Cell, 80, 155-165.
4. Fischer, U., Liu, Q. and Dreyfuss, G. (1997) The SMN-SIP1 complex has an essential role in spliceosomal snRNP biogenesis. Cell, 90, 1023-1029.
5. Pellizzoni, L., Yong, J. and Dreyfuss, G. (2002) Essential role for the SMN complex in the specificity of snRNP assembly. Science, 298, 1775-1779.
6. Pellizzoni, L., Kataoka, N., Charroux, B. and Dreyfuss, G. (1998) A novel function for SMN, the spinal muscular atrophy disease gene product, in pre-mRNA splicing. Cell, 95, 615-624.
7. Pagliardini, S., Giavazzi, A., Setola, V., Lizier, C., Di Luca, M., DeBiasi, S. and Battaglia, G. (2000) Subcellular localization and axonal transport of the survival motor neuron (SMN) protein in the developing rat spinal cord. Hum. Mol. Genet., 9, 47-56.
8. Pellizzoni, L., Charroux, B., Rappsilber, J., Mann, M. and Dreyfuss, G. (2001) A functional interaction between the survival motor neuron complex and RNA polymerase II. J. Cell Biol., 152, 75-85.
9. Pellizzoni, L., Baccon, J., Charroux, B. and Dreyfuss, G. (2001) The survival of motor neurons (SMN) protein interacts with the snoRNP proteins fibrillarin and GAR1. Curr. Biol., 11, 1079-1088.
10. Lorson, C.L., Hahnen, E., Androphy, E.J. and Wirth, B. (1999) A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscularatrophy. Proc. Natl Acad. Sci. USA, 96, 6307-6311.
11. McAndrew, P.E., Parsons, D.W., Simard, L.R., Rochette, C., Ray, P.N., Mendell, J.R., Prior, T.W. and Burghes, A.H. (1997) Identification of proximal spinal muscular atrophy carriers and patients by analysis of SMNT and SMNC gene copy number. Am. J. Hum. Genet., 60, 1411-1422.
12. Mailman, M.D., Heinz, J.W., Papp, A.C., Snyder, P.J., Sedra, M.S., Wirth, B., Burghes, A.H. and Prior, T.W. (2002) Molecular analysis of spinal muscular atrophy and modification of the phenotype by SMN2. Genet. Med., 4, 20-26.
13. Tzeng, A.C., Cheng, J., Fryczynski, H., Niranjan, V., Stitik, T., Sial, A., Takeuchi, Y., Foye, P., DePrince, M. and Bach, J.R. (2000) A study of thyrotropin-releasing hormone for the treatment of spinal muscular atrophy: a preliminary report. Am. J. Phys. Med. Rehabil., 79, 435-440.
14. Miller,R.G.,Moore,D.H.,Dronsky,V.,Bradley,W.,Barohn,R.,Bryan,W., Prior, T.W., Gelinas, D.F., Iannaccone, S., Kissel, J. et al. (2001) A placebo-controlled trial of gabapentin in spinalmuscular atrophy. J. Neurol. Sci., 191, 127-131.
15. Kinali, M., Mercuri, E., Main, M., De Biasia, F., Karatza, A., Higgins, R., Banks, L.M., Manzur, A.Y. and Muntoni, F. (2002) Pilot trial of albuterol in spinal muscular atrophy. Neurology, 59, 609-610.
16. Russman, B.S., Iannaccone, S.T. and Samaha, F.J. (2003) A phase 1 trial of riluzole in spinal muscular atrophy. Arch. Neurol., 60, 1601-1603.
17. Mercuri, E., Bertini, E., Messina, S., Pelliccioni, M., D'Amico, A., Colitto, F., Mirabella, M., Tiziano, F.D., Vitali, T., Angelozzi, C. et al. (2004) Pilot trial of phenylbutyrate in spinal muscular atrophy. Neuromuscul. Disord., 14, 130-135.
18. Weihl, C.C., Connolly, A.M. and Pestronk, A. (2006) Valproate may improve strength and function in patients with type III/IV spinal muscle atrophy. Neurology, 67, 500-501.
19. Liang, W.C.,Yuo,C.Y., Chang, J.G., Chen, Y.C.,Chang,Y.F.,Wang,H.Y., Ju, Y.H., Chiou, S.S. and Jong, Y.J. (2008) The effect of hydroxyurea in spinal muscular atrophy cells and patients. J. Neurol. Sci., 268, 87-94.
20. Brichta, L., Holker, I., Haug, K., Klockgether, T. and Wirth, B. (2006) In vivo activation of SMN in spinal muscular atrophy carriers and patients treated with valproate. Ann. Neurol., 59, 970-975.
21. Mercuri, E., Bertini, E., Messina, S., Solari, A.,D'Amico,A., Angelozzi,C., Battini, R., Berardinelli, A., Boffi, P., Bruno, C. et al. (2007) Randomized, double-blind, placebo-controlled trial of phenylbutyrate in spinal muscular atrophy. Neurology, 68, 51-55.
22. Tsai, L.K., Yang, C.C., Hwu, W.L. and Li, H. (2007) Valproic acid treatment in six patients with spinal muscular atrophy. Eur. J. Neurol., 14, e8-e9.
23. Rak, K., Lechner, B.D., Schneider, C., Drexl, H., Sendtner, M. and Jablonka, S. (2009) Valproic acid blocks excitability in SMA type I mouse motor neurons. Neurobiol. Dis., 36, 477-487.
24. Swoboda, K.J., Scott, C.B., Crawford, T.O., Simard, L.R., Reyna, S.P., Krosschell, K.J., Acsadi, G., Elsheik, B., Schroth, M.K., D'Anjou, G. et al. (2010) SMA CARNI-VAL trial part I: double-blind, randomized, placebo-controlled trial of L-carnitine and valproic acid in spinal muscular atrophy. PLoS ONE, 5, e12140.
25. Barber, S.C., Higginbottom, A., Mead, R.J., Barber, S. and Shaw, P.J. (2009) An in vitro screening cascade to identify neuroprotective antioxidants in ALS. Free Radic. Biol. Med., 46, 1127-1138.
26. Desai, U.A., Pallos, J., Ma, A.A., Stockwell, B.R., Thompson, L.M., Marsh, J.L. and Diamond, M.I. (2006) Biologically active molecules that reduce polyglutamine aggregation and toxicity. Hum. Mol. Genet., 15, 2114-2214.
27. Jarecki, J., Chen, X., Bernardino, A., Coovert, D.D., Whitney, M., Burghes, A., Stack, J. and Pollok, B.A. (2005) Diverse small-molecule modulators of SMN expression found by high-throughput compound screening: early leads towards a therapeutic for spinal muscular atrophy. Hum. Mol. Genet., 14, 2003-2018.
28. Riessland, M., Ackermann, B., Forster, A., Jakubik, M., Hauke, J., Garbes, L., Fritzsche, I., Mende, Y., Blumcke, I., Hahnen, E. et al. (2010) SAHA ameliorates the SMA phenotype in two mouse models for spinal muscular atrophy. Hum. Mol. Genet., 19, 1492-1506.
29. Westlund, B., Stilwell, G. and Sluder, A. (2004) Invertebrate disease models in neurotherapeutic discovery. Curr. Opin. Drug Discov. Dev., 7, 169-178.
30. Sleigh, J.N. and Sattelle, D.B. (2010) C. elegans models of neuromuscular diseases expedite translational research. Transl. Neurosci., 1, 214-227.
31. Buckingham, S.D. and Sattelle, D.B. (2008) Strategies for automated analysis of C. elegans locomotion. Invert. Neurosci., 8, 121-131.
32. Buckingham, S.D. and Sattelle, D.B. (2009) Fast, automated measurement of nematode swimming (thrashing) without morphometry. BMC Neurosci., 10, 84.
33. Gaud, A., Simon, J.M., Witzel, T., Carre-Pierrat, M., Wermuth, C.G. and Segalat, L. (2004) Prednisone reduces muscle degeneration in dystrophin-deficient Caenorhabditis elegans. Neuromuscul. Disord., 14, 365-370.
34. Braungart, E., Gerlach, M., Riederer, P., Baumeister, R. and Hoener, M.C. (2004) Caenorhabditis elegans MPP+ model of Parkinson's disease for high-throughput drug screenings. Neurodegener. Dis., 1, 175-183.
35. Marvanova, M. and Nichols, C.D. (2007) Identification of neuroprotective compounds of Caenorhabditis elegans dopaminergic neurons against 6-OHDA. J. Mol. Neurosci., 31, 127-137.
36. Giacomotto, J., Pertl, C., Borrel, C., Walter, M.C., Bulst, S., Johnsen, B., Baillie, D.L., Lochmuller, H., Thirion, C. and Segalat, L. (2009) Evaluation of the therapeutic potential of carbonic anhydrase inhibitors in two animal models of dystrophin deficient muscular dystrophy. Hum. Mol. Genet., 18, 4089-4101.
37. Miguel-Aliaga, I., Culetto, E., Walker, D.S., Baylis, H.A., Sattelle, D.B. and Davies, K.E. (1999) The Caenorhabditis elegans orthologue of the human gene responsible for spinal muscular atrophy is a maternal product critical for germline maturation and embryonic viability. Hum. Mol. Genet., 8, 2133-2143.
38. Burt, E.C., Towers, P.R. and Sattelle, D.B. (2006) Caenorhabditis elegans in the study of SMN-interacting proteins: a role for SMI-1, an orthologue of human Gemin2 and the identification of novel components of the SMN complex. Invert. Neurosci., 6, 145-159.
39. Briese, M., Esmaeili, B., Fraboulet, S., Burt, E.C., Christodoulou, S., Towers, P.R., Davies, K.E. and Sattelle, D.B. (2009) Deletion of smn-1, the Caenorhabditis elegans ortholog of the spinal muscular atrophy gene, results in locomotor dysfunction and reduced lifespan. Hum. Mol. Genet., 18, 97-104.
40. Dimitriadi, M., Sleigh, J.N., Walker, A.K., Chang, H.C.-H., Sen, A., Kalloo, G., Harris, J., Barsby, T., Walsh, B., Satterlee, J.S. et al. (2010) Conserved genes act as modifiers of invertebrate SMN loss of function defects. PLoS Genet., 6, e1001172.
41. Sun, Y., Grimmler, M., Schwarzer, V., Schoenen, F., Fischer, U. and Wirth, B. (2005) Molecular and functional analysis of intragenic SMN1 mutations in patients with spinal muscular atrophy. Hum. Mutat., 25, 64-71.
42. Ogawa, C., Usui, K., Aoki, M., Ito, F., Itoh, M., Kai, C., Kanamori-Katayama, M., Hayashizaki, Y. and Suzuki, H. (2007) Gemin2 plays an important role in stabilizing the survival of motor neuron complex. J. Biol. Chem., 282, 11122-11134.
43. McGovern, M., Yu, L., Kosinski, M., Greenstein, D. and Savage-Dunn, C. (2007) A role for sperm in regulation of egg-laying in the nematode C. elegans. BMC Dev. Biol., 7, 41.
44. Trent, C., Tsuing, N. and Horvitz, H.R. (1983) Egg-laying defective mutants of the nematode Caenorhabditis elegans. Genetics, 104, 619-647.
45. Altun-Gultekin, Z., Andachi, Y., Tsalik, E.L., Pilgrim, D., Kohara, Y. and Hobert, O. (2001) A regulatory cascade of three homeobox genes, ceh-10, ttx-3 and ceh-23, controls cell fate specification of a defined interneuron class in C. elegans. Development, 128, 1951-1969.
46. White, J.G., Southgate, E., Thomson, J.N. and Brenner, S. (1986) The structure of the nervous system of the nematode Caenorhabditis elegans. Phil. Trans. R. Soc. Lond. B. Biol. Sci., 314, 1-340.
47. Argov, Z. (2009) Management of myasthenic conditions: nonimmune issues. Curr. Opin. Neurol., 22, 493-497.
48. Brenner, S. (1974) The genetics of Caenorhabditis elegans. Genetics, 77, 71-94.
49. Piccioni, F., Roman, B.R., Fischbeck, K.H. and Taylor, J.P. (2004) A screen for drugs that protect against the cytotoxicity of polyglutamine-expanded androgen receptor. Hum. Mol. Genet., 13, 437-446.
50. Abbott, A. (2002) Neurologists strike gold in drug screen effort. Nature, 417, 109.
51. Heemskerk, J., Tobin, A.J. and Bain, L.J. (2002) Teaching old drugs new tricks. Meeting of the Neurodegeneration Drug Screening Consortium, 7-8 April 2002, Washington, DC, USA. Trends Neurosci., 25, 494-496.
52. Culetto, E., Baylis, H.A., Richmond, J.E., Jones, A.K., Fleming, J.T., Squire, M.D., Lewis, J.A. and Sattelle, D.B. (2004) The Caenorhabditis elegans unc-63 gene encodes a levamisole-sensitive nicotinic acetylcholine receptor alpha subunit. J. Biol. Chem., 279, 42476-42483.
53. Sleigh, J.N. (2010) Functional analysis of nematode nicotinic receptors. Biosci. Horizons, 3, 29-39.
54. Kaas, B., Vaidya, A.R., Leatherman, A., Schleidt, S. and Kohn, R.E. (2010) Technical report: exploring the basis of congenitalmyasthenic syndromes in an undergraduate course, using the model organism, Caenorhabditis elegans. Invert. Neurosci., doi: 10.1007/s10158-010-0101-2.
55. Andreassi, C., Jarecki, J., Zhou, J., Coovert, D.D.,Monani, U.R., Chen, X., Whitney, M., Pollok, B., Zhang,M., Androphy, E. et al. (2001) Aclarubicin treatment restores SMN levels to cells derived from type I spinal muscular atrophy patients. Hum. Mol. Genet., 10, 2841-2849.
56. Lunn, M.R., Root, D.E., Martino, A.M., Flaherty, S.P., Kelley, B.P., Coovert, D.D., Burghes, A.H., Man, N.T., Morris, G.E., Zhou, J. et al. (2004) Indoprofen upregulates the survival motor neuron protein through a cyclooxygenase-independent mechanism. Chem. Biol., 11, 1489-1493.
57. Andreassi, C., Angelozzi, C., Tiziano, F.D., Vitali, T., De Vincenzi, E., Boninsegna, A., Villanova, M., Bertini, E., Pini, A., Neri, G. et al. (2004) Phenylbutyrate increases SMN expression in vitro: relevance for treatment of spinal muscular atrophy. Eur. J. Hum. Genet., 12, 59-65.
58. Brichta, L., Hofmann, Y., Hahnen, E., Siebzehnrubl, F.A., Raschke, H., Blumcke, I., Eyupoglu, I.Y. and Wirth, B. (2003) Valproic acid increases the SMN2 protein level: a well-known drug as a potential therapy for spinal muscular atrophy. Hum. Mol. Genet., 12, 2481-2489.
59. Pulak, R. (2006) Techniques for analysis, sorting, and dispensing of C. elegans on the COPAS flow-sorting system. Methods Mol. Biol., 351, 275-286.
60. Krause, M., Fire, A., Harrison, S.W., Priess, J. and Weintraub, H. (1990) CeMyoD accumulation defines the body wall muscle cell fate during C. elegans embryogenesis. Cell, 63, 907-919.
61. Ardizzi, J.P. and Epstein, H.F. (1987) Immunochemical localization of myosin heavy chain isoforms and paramyosin in developmentally and structurally diverse muscle cell types of the nematode Caenorhabditis elegans. J. Cell Biol., 105, 2763-2770.
62. Avery, L. and Horvitz, H.R. (1989) Pharyngeal pumping continues after laser killing of the pharyngeal nervous system of C. elegans. Neuron, 3, 473-485.
63. Murray, L.M., Comley, L.H., Thomson, D., Parkinson, N., Talbot, K. and Gillingwater, T.H. (2008) Selective vulnerability of motor neurons and dissociation of pre-and post-synaptic pathology at the neuromuscular junction in mouse models of spinal muscular atrophy. Hum. Mol. Genet., 17, 949-962.
64. 2+ homeostasis in nerve terminals of severe spinal muscular atrophy mice. J. Neurosci., 30, 849-857.
65. Dubowitz, V. (1999) Very severe spinal muscular atrophy (SMA type 0): an expanding clinical phenotype. Eur. J. Paediatr. Neurol., 3, 49-51.
66. Nguyen, M., Alfonso, A., Johnson, C.D. and Rand, J.B. (1995) Caenorhabditis elegans mutants resistant to inhibitors of acetylcholinesterase. Genetics, 140, 527-535.
67. Miller, K.G., Alfonso, A., Nguyen, M., Crowell, J.A., Johnson, C.D. and Rand, J.B. (1996) A genetic selection for Caenorhabditis elegans synaptic transmission mutants. Proc. Natl Acad. Sci. USA, 93, 12593-12598.
68. Chan, Y.B., Miguel-Aliaga, I., Franks, C., Thomas, N., Trulzsch, B., Sattelle, D.B., Davies, K.E. and van den Heuvel, M. (2003) Neuromuscular defects in a Drosophila survival motor neuron gene mutant. Hum. Mol. Genet., 12, 1367-1376.
69. Kong, L., Wang, X., Choe, D.W., Polley, M., Burnett, B.G., Bosch-Marce, M., Griffin, J.W., Rich, M.M. and Sumner, C.J. (2009) Impaired synaptic vesicle release and immaturity of neuromuscular junctions in spinal muscular atrophy mice. J. Neurosci., 29, 842-851.
70. Schafer, W.R., Sanchez, B.M. and Kenyon, C.J. (1996) Genes affecting sensitivity to serotonin in Caenorhabditis elegans. Genetics, 143, 1219-1230.
71. Loria, P.M., Duke, A., Rand, J.B. and Hobert, O. (2003) Two neuronal, nuclear-localized RNA binding proteins involved in synaptic transmission. Curr. Biol., 13, 1317-1323.
72. Culetto, E. and Sattelle, D.B. (2000) A role for Caenorhabditis elegans in understanding the function and interactions of human disease genes. Hum. Mol. Genet., 9, 869-877.
73. Harris, T.W., Chen, N., Cunningham, F., Tello-Ruiz, M., Antoshechkin, I., Bastiani, C., Bieri, T., Blasiar, D., Bradnam, K., Chan, J. et al. (2004) WormBase: a multi-species resource for nematode biology and genomics. Nucleic Acids Res., 32, D411-D417.
74. Carre-Pierrat, M.,Mariol, M.C.,Chambonnier, L., Laugraud,A., Heskia, F., Giacomotto, J. and Segalat, L. (2006) Blocking of striated muscle degeneration by serotonin in C. elegans. J. Muscle Res. Cell Motil., 27, 253-258.
75. Lemeignan, M., Millart, H., Lamiable, D., Molgo, J. and Lechat, P. (1984) Evaluation of 4-aminopyridine and 3,4-diaminopyridine penetrability into cerebrospinal fluid in anesthetized rats. Brain Res., 304, 166-169.
76. Wafford, K.A. and Ebert, B. (2006) Gaboxadol-a new awakening in sleep. Curr. Opin. Pharmacol., 6, 30-36.
77. Wang, B., Downing, J.A., Petocz, P., Brand-Miller, J. and Bryden, W.L. (2007) Metabolic fate of intravenously administered N-acetylneuraminic acid-6-14C in newborn piglets. Asia Pac. J. Clin. Nutr., 16, 110-115.
78. Sherratt, R.M., Bostock, H. and Sears, T.A. (1980) Effects of 4-aminopyridine on normal and demyelinated mammalian nerve fibres. Nature, 283, 570-572.
79. Targ, E.F. and Kocsis, J.D. (1985) 4-aminopyridine leads to restoration of conduction in demyelinated rat sciatic nerve. Brain Res., 328, 358-361.
80. Thesleff, S. (1980) Aminopyridines and synaptic transmission. Neuroscience, 5, 1413-1419.
81. Thomsen, R.H. and Wilson, D.F. (1983) Effects of 4-aminopyridine and 3,4-diaminopyridine on transmitter release at the neuromuscular junction. J. Pharmacol. Exp. Ther., 227, 260-265.
82. Pinter, M.J., Waldeck, R.F., Cope, T.C. and Cork, L.C. (1997) Effects of 4-aminopyridine on muscle and motor unit force in canine motor neuron disease. J. Neurosci., 17, 4500-4507.
83. 1-42-induced cell signaling and functional responses in human microglia. J. Neurosci., 26, 11652-11664.
84. van Diemen, H.A., Polman, C.H., van Dongen, M.M., Nauta, J.J., Strijers, R.L., van Loenen, A.C., Bertelsmann, F.W. and Koetsier, J.C. (1993) 4-aminopyridine induces functional improvement in multiple sclerosis patients: a neurophysiological study. J. Neurol. Sci., 116, 220-226.
85. Goodman, A.D., Brown, T.R., Cohen, J.A., Krupp, L.B., Schapiro, R., Schwid, S.R., Cohen, R., Marinucci, L.N. and Blight, A.R. (2008) Dose comparison trial of sustained-release fampridine in multiple sclerosis. Neurology, 71, 1134-1141.
86. Goodman, A.D., Brown, T.R., Krupp, L.B., Schapiro, R.T., Schwid, S.R., Cohen, R., Marinucci, L.N. and Blight, A.R. (2009) Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial. Lancet, 373, 732-738.
87. Wolfe, D.L., Hayes, K.C., Hsieh, J.T. and Potter, P.J. (2001) Effects of 4-aminopyridine on motor evoked potentials in patients with spinal cord injury: a double-blinded, placebo-controlled crossover trial. J. Neurotrauma, 18, 757-771.
88. Miller, C. (2000) An overview of the potassium channel family. Genome Biol., 1, REVIEWS0004.
89. 3δ GABAA receptors characterized by fluorescence resonance energy transfer-derived measurements of membrane potential. J. Biol. Chem., 276, 38934-38939.
90. 3δ GABAA receptors. Br. J. Pharmacol., 136, 965-974.
91. Jia, F., Pignataro, L., Schofield, C.M., Yue, M., Harrison, N.L. and Goldstein, P.A. (2005) An extrasynaptic GABAA receptor mediates tonic inhibition in thalamic VB neurons. J. Neurophysiol., 94, 4491-4501.
92. McIntire, S.L., Jorgensen, E., Kaplan, J. and Horvitz, H.R. (1993) The GABAergic nervous system of Caenorhabditis elegans. Nature, 364, 337-341.
93. Schauer, R. (2009) Sialic acids as regulators of molecular and cellular interactions. Curr. Opin. Struct. Biol., 19, 507-514.
94. Iijima, R., Takahashi, H., Namme, R., Ikegami, S. and Yamazaki, M. (2004) Novel biological function of sialic acid (N-acetylneuraminic acid) as a hydrogen peroxide scavenger. FEBS Lett., 561, 163-166.
95. Hadjiconstantinou, M. and Neff, N.H. (1998) GM1 ganglioside: in vivo and in vitro trophic actions on central neurotransmitter systems. J. Neurochem., 70, 1335-1345.
96. Mocchetti, I. (2005) Exogenous gangliosides, neuronal plasticity and repair, and the neurotrophins. Cell. Mol. Life Sci., 62, 2283-2294.
97. Svennerholm, L., Brane, G., Karlsson, I., Lekman, A., Ramstrom, I. and Wikkelso, C. (2002) Alzheimer disease-effect of continuous intracerebroventricular treatment with GM1 ganglioside and a systematic activation programme. Dement. Geriatr. Cogn. Disord., 14, 128-136.
98. Schneider, J.S., Sendek, S., Daskalakis, C. and Cambi, F. (2010) GM1 ganglioside in Parkinson's disease: results of a five year open study. J. Neurol. Sci., 292, 45-51.
99. Iijima, R., Takahashi, H., Ikegami, S. and Yamazaki, M. (2007) Characterization of the reaction between sialic acid (N-acetylneuraminic acid) and hydrogen peroxide. Biol. Pharm. Bull., 30, 580-582.
100. Bacic, A., Kahane, I. and Zuckerman, B.M. (1990) Panagrellus redivivus and Caenorhabditis elegans: evidence for the absence of sialic acids. Exp. Parasitol., 71, 483-488.
101. Roy, N., Mahadevan, M.S., McLean, M., Shutler, G., Yaraghi, Z., Farahani, R., Baird, S., Besner-Johnston, A., Lefebvre, C., Kang, X. et al. (1995) The gene for neuronal apoptosis inhibitory protein is partially deleted in individuals with spinal muscular atrophy. Cell, 80, 167-178.
102. Soler-Botija, C., Ferrer, I., Gich, I., Baiget, M. and Tizzano, E.F. (2002) Neuronal death is enhanced and begins during foetal development in type I spinal muscular atrophy spinal cord. Brain, 125, 1624-1634.
103. Cuppen, E., Gort, E., Hazendonk, E.,Mudde, J., van de Belt, J., Nijman, I.J., Guryev, V. and Plasterk, R.H. (2007) Efficient target-selected mutagenesis inCaenorhabditis elegans: toward a knockout for every gene. Genome Res., 17, 649-658.
104. Wood, W.B. (1988) The Nematode Caenorhabditis elegans. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, pp. 12-13.
105. Shaham, S. (2006) Methods in Cell Biology (January 02, 2006). In the C. elegans research Community (ed.), WormBook. WormBook. doi/10.1895/wormbook.1.49.1, http://www.wormbook.org.